Akt-mediated FoxO1 inhibition is required for liver regeneration by Pauta Puig, Montse et al.
Akt-mediated FoxO1 inhibition is required for liver regeneration
Montse Pauta1,2,#, Noemi Rotllan2,3,4,#, Ana Fernández-Hernando2, Cedric Langhi7, Jordi 
Ribera1, Mingjian Lu8,&, Loreto Boix5, Jordi Bruix5, Wladimiro Jimenez1,6, Yajaira 
Suárez2,3,4, David A. Ford7, Angel Baldán7, Morris J. Birnbaum8, Manuel Morales-Ruiz1,6,*, 
and Carlos Fernández-Hernando2,3,4,*
1Department of Biochemistry and Molecular Genetics, Hospital Clinic of Barcelona, Institut 
d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigaciones 
Biomédicas en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain
2Departments of Medicine and Cell Biology, Leon H. Charney Division of Cardiology, New York 
University School of Medicine, New York, New York, USA
3Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, 
Connecticut, USA
4Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative 
Medicine and Department of Pathology, Yale University School of Medicine, New Haven, 
Connecticut, USA
5Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic of Barcelona, University 
of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERehd, 
Barcelona, Spain
6Department of Physiological Sciences I, University of Barcelona, Barcelona, Spain
7Edward A. Doisy Department of Biochemistry & Molecular Biology, and Center for 
Cardiovascular Research, Saint Louis University, Saint Louis, Missuri, USA
8Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, Pennsylvania, USA
Abstract
Understanding the hepatic regenerative process has clinical interest, since the effectiveness of 
many treatments for chronic liver diseases is conditioned by an efficient liver regeneration. 
Experimental evidence points to the need of a temporal coordination between cytokines, growth 
factors and metabolic signaling pathways to enable successful liver regeneration. One intracellular 
mediator that acts as a signal integration node for these processes is the serine-threonine kinase 
Akt/PKB (Akt). To investigate the contribution of Akt during hepatic regeneration, we performed 
partial hepatectomy in mice lacking Akt1, Akt2 or both isoforms. We found that absence of Akt1 
*Corresponding authors: Manuel Morales-Ruiz, Ph.D., Department of Biochemistry and Molecular Genetics, Hospital Clinic of 
Barcelona, 170 Villarroel St, Barcelona, 08036, Spain, Tel: 011-34-932275466; Fax: 011-34-932275697; morales@clinic.ub.es., 
Carlos Fernandez-Hernando, Ph.D., Vascular Biology and Therapeutics Program, Yale University School of Medicine, 10 Amistad 
Street, New Haven, CT06520, Tel: 2037374615; Fax: 2037372290; carlos.fernandez@yale.edu.
#These authors contributed equally to this work.
&Present address: Lilly China Research and Development Center. Shanghai, People’s Republic of China.
HHS Public Access
Author manuscript
Hepatology. Author manuscript; available in PMC 2017 May 01.
Published in final edited form as:













or Akt2 does not influence liver regeneration after partial hepatectomy. However, hepatic-specific 
Akt1 and Akt2 null mice show impaired liver regeneration and increase mortality. The major 
abnormal cellular events observed in total Akt deficient livers were a marked reduction in cell 
proliferation, cell hypertrophy, glycogenesis and lipid droplets formation. Most importantly, liver-
specific deletion of FoxO1, a transcription factor regulated by Akt, rescued the hepatic 
regenerative capability in Akt1 and Akt2 deficient mice and normalized the cellular events 
associated with liver regeneration. These results establish an essential role for the Akt-FoxO1 
signaling pathway during liver regeneration that has not been previously described.
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The liver is the only human internal organ that maintains a remarkable ability to regenerate 
through a process of compensatory hepatocellular hypertrophy and hyperplasia (1, 2). This 
phenomenon has also been described in experimental models of liver regeneration, such as 
the well-characterized model of two-thirds partial hepatectomy (PH) in rodents. For 
instance, partially hepatectomyzed mice recover their total hepatic mass after 7–10 days (3). 
This regenerative capability of the liver protects the organisms from hepatic parenchyma 
loss that may be caused by chronic infection, traumatic injury or liver poisoning. 
Understanding the hepatic regenerative process has clinical interest, since the effectiveness 
of many treatments for chronic liver diseases, such as resection of tumors and donor liver 
transplantation, is conditioned by an efficient liver regeneration (4, 5). In the context of 
hepatocellular carcinoma (HCC), these malignant tumors usually develop in cirrhotic livers, 
which are characterized by a poor regenerative capacity. Thus, liver resection in cirrhotic 
patients is a risky therapeutic decision. This is due to several factors, being the diminished 
regenerative capability of the remnant liver one of them (6, 7). Accordingly, it is necessary 
to identify new therapeutic targets to stimulate liver regeneration.
Abundant experimental evidence points to multiple signaling molecules and mechanical 
events that start very early after PHx and enable successful liver regeneration. These include 
changes in the enzymatic activation of extracellular matrix remodelers (e.g. urokinase 
plasminogen activator, MMP-9), relative changes in blood flow volume in relation to the 
remaining hepatic sinusoid, the increment on the bioavailability of certain growth factors 
(HGF, EGFR ligands), hormones (noradrenalin, serotonin) and cytokines; the activation of 
transcription factors (STAT3, NF-κB, Notch-NICD, β-catenin) and changes in the 
transcriptome of hepatocytes. These initial changes prime quiescent hepatocytes to progress 
through the cell cycle, while preserving their homeostatic metabolic function. Subsequently, 
parenchyma and then non-parenchymal cells proliferate until the liver recovers its lost mass 
and, concurrently, a no well define termination phase coordinates the repression of cell 
proliferation (8, 9). All these findings have helped to increase our knowledge on the 
mechanisms accounting for liver regeneration. However, we have not reached a full 
understanding of this process and some questions are still poorly define, such as for example 
how the metabolic state of the organism is integrated with this regenerative process. One 
intracellular mediator that plays a major role in cell growth, cell proliferation and glucose/fat 
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metabolism is the serine-threonine kinase Akt/PKB (Akt). In mammals, there are three Akt 
isoforms (Akt1, Akt2 and Akt3) encoded by three separate genes that share sequence 
homology and that recognize the same phosphorylation motif (10). Experiments performed 
in mice that were deficient in each of the Akt/PKB isoforms have shown that despite their 
homology, the three Akt isoforms have distinct biological functions. For instance, mice 
deficient in Akt1 exhibit impaired growth (11), vascular dysfunction and decreased 
leukocyte recruitment in inflammation model (12, 13). Mice deficient in Akt2 show defects 
in glucose homeostasis and exhibit insulin resistance (14) and Akt3−/− mice exhibit impaired 
brain development (15). Another factor that may diversify the biological role of the Akt 
isoforms is their differential tissular expression. In this regard, Akt1 and Akt2 are the only 
isoforms expressed in the liver, being Akt2 the most abundant isoform accounting for near 
85% of total Akt hepatic protein(15).
Preliminary evidence suggests that Akt may play a major role in liver regeneration. For 
instance, 1) partial hepatectomy induces Akt phosphorylation (16–18). 2) The blockade of 
Akt activators, such as PI3-K or PDK1, is associated with poor liver regeneration (19, 20). 3) 
Persistent stimulation of PI3-K/Akt pathway in hepatocytes resulted in an enlarged liver 
mass (21). Despite these observations, the role of Akt and its different isoforms during liver 
regeneration remains poorly understood. Thus, to define the role of Akt during liver 
regeneration, we performed PH in mice deficient in Akt1, Akt2 or both isoforms. We show 
that absence of Akt1 or Akt2 does not influence liver regeneration after PH. Importantly, 
deletion of both isoforms results in impaired liver regeneration and increased mortality. The 
hepatic double mutant mice show a marked reduction in cell proliferation, cell hypertrophy, 
glycogenesis and neutral lipid accumulation lipid droplets after PH. Of note, genetic ablation 
of FoxO1 in the liver rescues hepatocyte proliferation, glucose homeostasis and survival in 
Akt1/Akt2 deficient mice. In agreement with these in vivo results, pharmacological 
inhibition of FoxO1 in mouse primary hepatocytes stimulates the expression of proliferative 




Experiments were performed in eight-old-week male Akt1−/− and Akt2−/− (Jackson 
Laboratory, CA, USA), Akt1loxP/loxP (22), Akt2loxP/loxP (23) FoxO1loxP/loxP (24) mice. In 
addition, we generated the Akt1loxP/loxP;Akt2loxP/loxP;FoxO1loxP/loxP mice (TLKO) by 
crossing the Akt1loxP/loxP;Akt2loxP/loxP mice (DLKO) with the FoxO1loxP/loxP mice, as 
previously reported (25). These mice were on the 129–C57BL–6J/FVB mixed background. 
We recovered the Akt1loxP/loxP;Akt2loxP/loxP mice on the same background and used them to 
compare the DLKO against TLKO (Akt1loxP/loxP;Akt2loxP/loxP and FoxO1loxP/loxP). All 
animals were kept under constant temperature and humidity in a 12 hours controlled dark/
light cycle. Mice were fed ad libitum on a standard pellet diet. The liver specific Akt1/Akt2 
(DLKO) and Akt1/Akt2/FoxO1 (TLKO) deficient mice were obtained by injecting eight-old 
week male with adeno-associated virus encoding Cre-recombinase under the control of the 
thyroxine-binding globulin (Tbg) promoter (AAV8-Tgb-Cre), which led to the hepatocyte-
Pauta et al. Page 3













specific deletion of both Akt1 and Akt2. The experiments were performed 2 weeks after 
virus injection.
Surgical Procedure
All surgeries were carried out under Isoflurane (Sigma-Aldrich, St. Louis, MO) anesthesia. 
Partial hepatectomy (PH) was performed according to the technique described by Higgins 
and Anderson (3). The abdomen was opened via a midline incision. Two thirds of the liver 
(median and left lobes) was removed. After PH, WT mice (n=21), Akt1−/− mice (n=12), 
Akt2−/− mice (n=21), DLKO (n=12) and TLKO (n=12) were sacrificed at different time 
points: 2, 4 and 6 days. The regenerating bottom right lobe was snap-frozen into liquid 
nitrogen and the upper right lobe was fixed in either: 1) 4% paraformaldehyde at 4°C, 
cryoprotected overnight in 30% sucrose solution, embedded in OCT medium (Tissue-Tek® 
O.C.T™ Compound, SAKURA) or 2) 10% buffered formaldehyde and embedded in 
paraffin for future processing. The percentage of liver regeneration was calculated following 
the formula: weight of non-removed lobes/ Total body weight of mice.
Histology
Frozen sections of 8-µm were rehydrated and lipid droplets deposition was detected by Oil 
Red O staining (Sigma-Aldrich, St Louis, MO, USA). Sections were rinsed with 60% 
isopropanol and stained for 20 minutes with filtered Oil Red-O solution (0,5% in 
isopropanol followed by a 60% dilution in distilled water). After two rinses with 60% 
isopropanol and distilled water, slides were counterstained with hematoxylin for 4 minutes, 
rinsed with water and mounted. Hepatic glycogen content was assessed in 8-µm liver 
sections that were embedded in paraffin and fixed in 10% buffered formaldehyde solution. 
Sections were periodic acid-Schiff (PAS)-stained, according to the manufacturer’s 
instruction (Sigma-Aldrich, St Louis, MO, USA) and counterstained with hematoxylin 
(Sigma-Aldrich, St Louis, MO, USA). Total hepatocyte cell area was quantified in 
hematoxylin eosin-stained liver sections. The cell areas in the photomicrographs were 
measured using the software ImageJ (version 1.37, National Institutes of Health, Bethesda, 
MD). All the histology images were taken using a light microscope coupled with a digital 
image acquisition system (Nikon Eclipse E600, Kawasaki, Kanagawa, Japan).
Immunofluorescence
Frozen sections of 8-µm were rehydrated, blocked with 5% normal goat serum (NGS) and 
incubated with mouse anti-Ki-67 (1:100, Abcam) or rabbit anti-CCND1 (1:100, Cell 
Signaling). Controls without primary antibodies were revealed with Alexa-597 goat-anti-
mouse IgG (1:1000, Invitrogen). Samples were analyzed with a fluorescence microscope 
(Nikon Eclipse E600, Kawasaki, Kanagawa, Japan). The cells were counterstained with 
DAPI to visualize the nuclei.
Western blot analysis
Tissue lysates were prepared in a lysis buffer (Tris–HCl 20 mM pH 7.4 containing 1% Triton 
X-100, 0.1% SDS, 50 mM NaCl, 2.5 mM EDTA, 1 mM Na4P2O7 10H2O, 20 mM NaF, 1 
mM Na3VO4, 2 mM Pefabloc and Complete® from Roche). Proteins were separated on a 
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7.5% SDS-polyacrylamide gel (Mini Protean III, BioRad, Richmond, Ca) and transferred for 
2 hours at 4°C to nitrocellulose membranes of 0,45 µm (Transblot Transfer Medium, 
BioRad, Richmond, CA) that were stained with Ponceau-S red as a control for protein 
loading. The membranes were incubated at 4°C overnight with the following antibodies; 
rabbit anti-FoxO1 (1:1000, Cell Signaling), rabbit anti-phospho-FoxO1 (Ser256) (1:1000, 
Cell Signaling), rabbit anti-Phospho-Akt (Ser473) (1:1000, Cell Signaling), mouse anti-Akt1 
(1:1000, Cell Signaling), anti Rabbit-Akt2 (1:1000, Cell Signaling), rabbit anti-Akt (1:5000, 
Cell signaling), rabbit anti-CCND1 (1:1000, Cell Signaling), mouse anti-PCNA (1:1000, 
Sigma), HSP90 and Tubulin. Next, the membranes were incubated with a donkey ECL-anti-
rabbit IgG or sheep ECL-anti-mouse IgG peroxidase-conjugated secondary at 1:5000 
dilution (GE Healthcare) for 1 hour at room temperature. The bands were visualized using 
LuminataTM Forte Western HRP Substrate (Millipore) and ImageQuantTM LAS 4000 (GE 
Healthcare). Alternatively, the membranes were incubated with secondary fluorescently-
labeled antibodies (Molecular Probes, Invitrogen) and proteins bands were visualized using 
Odyssey Infrared Imaging System (LI-COR Biotecnology). Densitometry analysis of the 
gels was performed using the imaging software Image J [version 1.37, National Institutes of 
Health, Bethesda, MD (NIH)].
Biochemical assays
For glucose measurement, 1–2 mm of tissue was cut from the tail tip of mice with a scalpel 
early in the morning. Then blood was obtained by direct flow, collected in test strips and 
directly measured in a glucometer (Accu-Chek Active; Roche Diagnostics, Manheim, 
Germany).
Lipidomics
Livers (50 mg) were homogenized in 500 µL of PBS, and lipids were extracted from 100 µL 
of the homogenate in the presence of internal standards for each lipid class. The different 
lipid classes were quantified from the chloroform extracts using shotgun lipidomics based on 
class separation by MS/MS specific methods, as previously described (25).
Statistics
In the case of homoscedasticity and normally distributed data (assessed by Shapiro-Wilk 
test) groups were compared using two-sided Student's t-test or ANOVA (analysis of 
variance) for independent samples. For other types of data, the two-sided Student's t-test 
Mann–Whitney U test or the Kruskal–Wallis test was used. Tukey's test (with ANOVA) or 
Dunn's test (with Kruskal-Wallis) were used as post hoc test to perform pairwise 
comparisons. Survival curves after PH were generated using the product limit method of 
Kaplan and Meier. The survival curves were compared using the log-rang test. Differences 
were considered to be significant at a P value <0.05. Data are presented as the mean ± 
standard error of the mean (SEM).
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All animal experiments were approved by the Institutional Animal Care Use Committee of 
New York University Medical Center, the University of Pennsylvania IACUC and the 
Investigation and Ethics Committees of the Hospital Clinic.
RESULTS
Hepatic Akt1 and Akt2 deficiency results in impaired liver regeneration and increased 
mortality after partial hepatectomy
To study the contribution of Akt1 and Akt2 during liver regeneration, we performed two-
thirds partial hepatectomy (PH) in wild-type (WT), Akt1−/−, Akt2−/− and DLKO mice. Liver 
specific mice deficient in Akt1 and Akt2 (DLKO) were generating by breeding Akt2 loxP/loxP 
with Akt1loxP/loxP mice and injecting them with an adeno-associated virus expressing Cre 
recombinase under the control of the thyroxine-binding globulin promoter (AAV8-Tgb-Cre), 
which led to the liver –specific deletion of Akt1 and Akt2 (referred to here as DLKO). 
Western blot analysis confirmed the efficient deletion of Akt1 and Akt2 in the liver from the 
DLKO mice 2 weeks after virus injection (Fig. 1A). Morphologically, the livers from 
Akt1−/− and DLKO mice are smaller than the livers from WT and Akt2−/− mice (data not 
shown). Despite the difference in liver size, the liver to body-weight ratio found in Akt1−/− 
and Akt2−/− mice was similar to the WT mice (Fig. 1B). However, the double mutant mice 
presented a marked decrease of the liver/body weight ratio compared to the other groups of 
mice, suggesting that Akt is required for physiological liver growth (Fig. 1B). To study the 
contribution of Akt1 and Akt2 during liver regeneration, we performed two-thirds PH in 
WT, Akt1−/−, Akt2−/− and DLKO mice. Mice were sacrificed 2, 4, and 6 days after PH and 
the wet liver remnant weight, together with the total body weight, was used to calculate the 
hepatic regenerative rate. WT, Akt1−/− and Akt2−/− mice showed a significant and 
progressive increase in the hepatic regenerative index (from 2–2.5 % at second day to ~3.4% 
at sixth day) after PH, consistent with what was expected for an efficient liver regeneration. 
In contrast, DLKO mice showed an increase in the regenerative index early after PH that was 
interrupted after day 4 without further progression (Fig. 1C). This abnormality observed in 
the DLKO mice was associated with a marked increase in mortality, compared with WT, 
Akt1−/− and Akt2−/− mice, that was evident from day 2 after PH (Fig. 1D).
Liver-specific FoxO1 deletion improved survival rates and liver function in DLKO mice 
after PH
The FoxO1 transcription factor is a downstream target of Akt and considerable data support 
a major role of this signaling pathway on the glucoregulation (25, 26). This information 
points to FoxO1 as a potential mediator of the impaired hepatic regeneration observed in 
DLKO mice. Thus, we determined the contribution of FoxO1 during hepatic regeneration in 
mice lacking Akt1, Akt2 and FoxO1 (TLKO). To this end, WT, DLKO and TLKO mice 
were partially hepatectomized and sacrificed at 0, 2, 4, and 6 days after surgery. DLKO and 
TLKO mice showed no significant differences in the liver to body weight ratio before PH. At 
the second day post-hepatectomy, the TLKO mice showed a significant increase in the 
hepatic regenerative index, compared with the DLKO mice (Fig. 1E). Despite this 
improvement in liver regeneration, liver/total body weight values were remained lower in the 
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TLKO mice compared to WT mice (Fig. 1E). After 4 days post-hepatectomy, the DLKO and 
the TLKO mice showed similar regenerative indexes. However, TLKO mice showed a 
survival rate comparable to that observed in WT mice at 6 days post-hepatectomy (Fig. 1F). 
This remarkable result contrasts with the high mortality observed in the hepatectomized 
DLKO group (Fig. 1D) and pointed to the activation of FoxO1 as the mechanism through 
which hepatic Akt deficiency increases mortality after PH.
After PH, the remnant liver has to compensate the functionality of the resected hepatic mass. 
This is achieved through both hepatocellular hypertrophy and hyperplasia that helps 
maintaining key processes such as glucose homeostasis. Failure to do so may result in liver 
failure and death (1, 2, 8). We expected the high survival rate observed in TLKO mice to be 
accompanied by an improved control of glucose homeostasis, compared with DLKO. To 
verify this assumption we measured glycemia and hepatic glycogen storage in WT, DLKO 
and TLKO mice. Before the PH was performed, DLKO mice showed significant higher 
levels of blood glucose concentration compared with WT mice (Fig. 1G; 0 days after PH). 
We have previously described this impaired regulation of the glucose homeostasis in DLKO 
mice in response to fasting and feeding conditions(25). Under these experimental conditions, 
we demonstrated the occurrence of hyperglycemia, insulin resistance and lower levels of 
glycogen content in the DLKO(25). After PH, WT mice developed early hypoglycemia and 
this situation was normalized after 72 hours post-PH, compared with its basal level. DLKO 
mice also developed a marked hypoglycemia starting at 12 hours after PH. In addition, 
DLKO mice showed lower levels of blood glucose concentration at 12 and 24 hours after 
PH, compared with WT mice. DLKO mice that survived after this period of time displayed a 
glycemic profile significantly different from the WT mice and characterized by a severe 
hyperglycemia after 72 hours. In TLKO livers, despite the lack of Akt, the liver adapts 
appropriately to maintain the euglycemia in basal conditions (Fig. 1G; 0 days after PH). In 
addition, TLKO mice normalized their glucose profile after PH, and reversed the 
hyperinsulinemia associated with the liver-specific Akt1 and Akt2 deficiency at later times 
after PH (Fig. 1G). We next measured hepatic glycogen content in liver samples isolated 
from WT, DLKO and TLKO mice before and after PH. We found that the three experimental 
groups showed similar levels of hepatic glycogen before PH (Fig. S1). Glycogen storage 
diminished drastically in all groups of mice at day 2 post-hepatectomy (Fig. S1). This 
phenomenon is likely due to fasting that experienced the mice after surgery and the need of 
the remnant liver to maintaining euglycemia, despite the loss of hepatic mass. WT and 
TLKO recovered their baseline levels of glycogen at day 6 (Fig. S1). By contrast, hepatic 
glycogen was barely present in DLKO mice after 6 of PH (Fig. S1). Thus, loss of hepatic 
FoxO1 activity allows improved glucose metabolism in Akt-deficient hepatectomized livers.
Loss of FoxO1 activity restored hepatocellular hyperplasia in Akt-deficient regenerative 
livers
To further understand the mechanism by which FoxO1 deficiency improves survival and 
liver function in Akt-null livers, we quantified hepatocellular hypertrophy and hyperplasia 
following PH. To this end, we measured the cellular area of hepatocytes in basal conditions 
and at different times following PH. Histological examination of livers in basal conditions 
revealed that loss of Akt1 and Akt2 in livers was associated with a significant decrease in 
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hepatocyte area (Fig. 2, quantified in the bottom panel). The differences in cell size were 
also apparent in the TLKO mice although to a less extent (Fig. 2, quantified in the bottom 
panel). Two days after PH, WT mice showed a significant increase in hepatocyte cell area. 
This hepatocellular hypertrophy decreased in the following days and reached levels similar 
to baseline values at day 6 post-hepatectomy (Fig. 2, quantified in the bottom panel). By 
contrast, DLKO and TLKO mice showed a less pronounced hypertrophic response 
significantly lower than WT mice (Fig. 2, quantified in the bottom panel). FoxO1 deficiency 
in TLKO mice partially correct the poor hypertrophy observed in the context of dual Akt1/
Akt2 loss. However, the maximum increase in cell area observed in TLKO mice was far 
lower than the cell area quantified in WT mice at day 2 and 4.
As described above, FoxO1 deficiency does not dramatically alter hepatocyte cell area in 
DLKO mice after PH. Therefore, other mechanisms different from cellular hypertrophy may 
account for the improvement in hepatic regeneration and survival observed in TLKO mice. 
Therefore, we studied hepatocellular hyperplasia by measuring the expression of cell cycle 
markers. Western blot analysis confirmed efficient deletion of Akt1, Akt2 and FoxO1 in 
livers of DLKO and TLKO, respectively (Fig. 3). WT mice showed a significant decrease of 
Akt phosphorylation at the S473 phosphorylation site after surgery. However, detectable 
levels of Akt phosphorylation are maintained during the post-hepatectomy period and are 
slightly increased at day 4, compared with day 2 post-hepatectomy (Fig. 3). This result 
suggests that despite the initial reduction in Akt phosphorylation, likely due to post-surgical 
fasting, Akt activity is needed for the whole regenerative process. CCND1 and PCNA 
expression was significantly increased in WT mice after 2 days of performing PH, compared 
with basal condition (Fig. 3, quantified in right panels). In contrast, CCND1 and PCNA 
expression was markedly attenuated in DLKO after PH (Fig. 3, quantified in right panels). In 
this experimental condition the expression of CCND1 was absent after 2 days post-
hepatectomy and barely present at 4 days post-hepatectomy. The expression profile of 
PCNA, a cell proliferating marker, in DLKO also differed from WT mice and was 
characterized by a delay in its expression. While the PCNA expression in DLKO occurred 
on day 4 post-hepatectomy, we found a significant expression of this marker in WT mice 2 
days after PH (Fig. 3). We also assessed the presence of immunoreactivity for CCND1 and 
Ki-67 in all the experimental groups before and after PH. The results showed that both 
CCND1 and Ki-67 expression were absent in the liver from the experimental groups studied 
before PH (Fig. 4A and Fig. S2A). Additionally, cell death (measured by TUNEL) was 
undetectable in the WT, DLKO or TLKO livers before PH (Fig. S2B).
The reduced expression of CCND1 and PCNA observed in DLKO mice correlated with an 
impaired hepatocellular proliferation that was quantified by Ki-67 immunostaining (Fig. 4). 
WT mice showed a significant population of Ki-67 positive cells at day 2 post-hepatectomy 
(Fig. 4B, upper panels and quantified in 4E). Thereafter, this immunostaining declined 
markedly. This result is in agreement with similar reports that describe an early proliferation 
of hepatocyte after liver resection (1, 2). In contrast, DLKO mice showed barely detectable 
Ki-67 immunostaining at day 2 after PH (Fig. 4B, middle panels and quantified in 4E). In 
the DLKO mice that survive after PH, Ki-67 immunostaining increased slightly after 4 days 
(Fig. 4C, middle panels and quantified in 4E) but overall, DLKO mice showed a dramatic 
decrease of hepatic cellular proliferation, compared with WT mice. Of note, FoxO1 
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deficiency in the context of dual loss of Akt1/Akt2 (TLKO mice) normalized the expression 
of CCND1 and PCNA (Fig. 3, quantified in right panels) and restored hepatocellular 
proliferation to levels comparable to that of WT (Fig. 4A–D), bottom panels and quantified 
in 4E). Similarly, we found a marked increase expression of proliferative markers (PCNA, 
Ki-67 and CCND1) in mouse primary hepatocytes treated with a FoxO1 specific inhibitor 
(AS1842856) or in combination with the Akt1/Akt2 inhibitor (A6730) (Fig. S3A, 
quantification is shown in bottom panels). As expected, hepatic cellular density was 
significantly higher in cells treated with Akt and FoxO1 inhibitors compared to cells treated 
with Akt inhibitor alone (Fig. S3B). Taken together, these in vivo and in vitro results 
strongly suggests that Akt allows cell proliferation in regenerative livers through the 
suppression of FoxO1 activity.
Genetic ablation of FoxO1 restored hepatic lipid accumulation and nearly normalized the 
hepatic lipidome in Akt-deficient regenerative livers
Early stages of liver regeneration are characterized by the formation of hepatocellular lipid 
droplets and changes in the hepatic lipidome. Several preclinical studies showed that 
alterations of these features impair hepatocellular proliferation during liver regeneration 
(27). To explore whether the hepatic loss of Akt may additionally affects lipid metabolism, 
we characterized both the hepatic lipid accumulation and the lipidomic profile of livers from 
WT, DLKO and TLKO mice before and after PH. Oil-red O staining of liver sections from 
WT and TLKO mice displayed modest accumulation of lipids before PH (Fig. 5A). As a 
response to PH, WT mice showed a significant steatosis characterized by the presence of 
microvesicular lipid droplets. This accumulation of lipids was evident as early as 2–4 days 
post-partial hepatectomy and declined thereafter. In contrast, DLKO mice failed to 
accumulate lipid droplets under normal physiological conditions or following PH. 
Interestingly, TLKO mice re-established lipid droplet formation in Akt1 and Akt2 deficient 
livers. At day 2 post-hepatectomy, the livers from TLKO mice displayed microvesicular 
steatosis that was comparable to the levels found in WT mice. At day 4 post-hepatectomy, 
the microvesicular steatosis became significant macrovesicular steatosis, which was 
characterized by more and larger lipid droplet accumulation, compared with WT condition 
at the same time point. Finally, the transient steatosis observed in both WT and TLKO 
resolved at day 6 post-hepatectomy (Fig. 5A).
We further assessed the lipid profile in all groups of mice before and after PH. As shown in 
Fig. 5B, the hepatic lipidome of DLKO differed significantly from WT mice before and after 
PH. Before PH, DLKO mice showed marked alterations in the concentration of cholesterol 
esters (CE), phosphatidylcholine (PC), sphingomyelin (SM), triglycerides and free fatty 
acids (FFA), compared with WT animals. This data suggest that the normal activity of 
hepatic Akt is required to maintain the lipid metabolism balance in normal conditions. After 
PH, WT mice showed a significant increase in CE, triglycerides and FFA that reached a 
maximum concentration at 2 days and declined thereafter (Fig. 5B). These changes agreed 
with the temporal distribution of lipid droplets observed in Fig. 5A and are consistent with 
the concept that lipid droplets are lipid structures enriched in cholesterol esters and 
triglycerides (27, 28). By contrast, the concentration of CE, triglycerides, (TG) and FFA 
remained significantly lower in DLKO mice compared with WT mice, without major 
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changes throughout the hepatic regeneration. As well as cholesterol, another major structural 
component of cellular membranes whose concentration diminished in the liver of DLKO 
mice was PC (Fig. 5B). This finding is relevant considering that decrease of PC in lipid 
droplets from regenerative livers has previously been associated with quiescent hepatocytes 
(29). The increased in SM concentration was the only upward trend observed in DLKO mice 
early after PH, which almost double the concentration observed in WT mice at day 2 (Fig. 
5B). Consistent with the Oil-red O staining experiments, genetic ablation of Foxo1 in Akt 
deficient mice tended to normalized the hepatic lipidome before and after PH (Fig. 5B). 
Comparing hepatectomized TLKO and WT mice, we only observed differences in the 
concentration of TG and phosphatidylethanolamine (PE) at days 2 and 6 post-hepatectomy, 
respectively (Fig. 5B). The 2.5-fold increase in triglycerides observed in TLKO mice, 
compared with WT, may be responsible for the increase in macrovesicular steatosis that we 
detected in this experimental group. We also detected an increase of FFA concentration in 
TLKO mice at day 2, although these values did not reach statistical significance (Fig. 5B).
DISCUSSION
Our study identifies Akt-FoxO1 as a major signaling pathway for controlling liver 
regeneration. Using a triple liver conditional knockout mouse model, we demonstrate that 
Akt-FoxO1 regulates a number of physiological processes associated with liver regeneration 
including cell proliferation and glucose and lipid metabolism.
Akt/PKB protein is a serine/threonine kinase that is activated in response to various stimuli, 
such as growth factors and cytokines. Upon the recruitment of Akt to the plasma membrane, 
its Ser473 and Thr308 amino acid residues are phosphorylated by mTORC2 complex and 
PDK1, respectively (30, 31). In this state of phosphorylation, Akt acquires serine/threonine 
kinase activity against proteins containing the RxRxxS/T motif. This Akt-dependent 
phosphorylation causes the inhibition or activation of key regulatory proteins that control 
such cellular processes as cell growth (inhibition of PRAS40 and TSC2), apoptosis 
(inhibition of GSK3, FOX transcription factors, BAD and Caspase-9 and activation of 
MDM2), metabolism (inhibition of PRAS40, TSC2, GSK3 and FOX transcription factors), 
proliferation (inhibition of TSC2, PRAS40, p27, GSK3, FOX transcription factors and 
activation of MDM2) (10) and angiogenesis (activation of EDG1 and eNOS) (32, 33).
Previous reports have demonstrated the hepatoprotective properties of Akt in experimental 
models of cirrhosis and ischemia-reperfusion injury (34–37). However, its role in liver 
regeneration has only been investigated by correlation or through non-specific inhibitors that 
may affect other key molecular mediators. For instance, the majority of these studies aimed 
at evaluating the phosphorylation kinetics of Akt after PH. These studies agree that Akt is 
markedly activated early after the surgical procedure (16–18). In addition, the treatment of 
partially hepatectomized mice with LY294002 (38), wortmannin, small interfering RNA 
targeting PI3-K (20), Rapamycin (39) or PTEN inhibitors (40) impaired liver regeneration in 
response to PH.
Non-specific genetic-targeting of the Akt signaling pathway also suggests the participation 
of this serine/threonine kinase in liver regeneration. Haga et al. (19) showed that liver-
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specific PDK1 knockout mice presented a poor liver regeneration, impaired hepatocyte 
hypertrophy and high mortality rate after PH. Interestingly, PDK1 deficient mice maintain 
hepatocellular proliferation after PH to values comparable to those of WT mice. Although 
this study point to a major function of PDK1 in the hepatic regenerative process, it does not 
allow drawing firm conclusions about the role of Akt in liver regeneration. One of the 
reasons that support this assertion is that PDK1 also targets other key mediators that may 
affect cell hypertrophy and division, such as S6K, RSK and some PKC isoforms (41, 42). 
The authors tried to overcome this limitation using a “pif-pocket” mutant of PDK1, which 
allows PDK1 to signal exclusively to Akt. Under this experimental setting, adenoviral 
transduction of the active pif-pocket mutant of PDK1 restored hepatocellular hypertrophy in 
partially hepatectomyzed PDK1 null mice. The main limitation of this approach is that 
adenoviral treatment does not guaranty high transduction efficiency of the PDK1 mutant into 
the liver. Therefore, Akt activity would be restored only in a little percentage of hepatocytes, 
while the full deficiency of PDK1 would be maintained in the rest. In addition, other 
phosphorylation sites than Thr308 may regulate Akt activity under different biological 
contexts. For example, phosphorylation in Akt Ser473 by mTORC2, DNA-dependent protein 
kinase, integrin-linked kinase or mitogen-activated protein kinase-activated protein kinase-2 
is required for full activation (30, 43). AktS477/T479 phosphorylation triggered by cyclin-
dependent kinase 2/cyclinA, mTORC2 or DNA-PK is essential for Akt activation (44). Akt 
phosphorylation in Tyr315, Tyr326 (by Src-related tyrosine kinases) (45) and Tyr176 (by 
Ack1) (46) play also a role in Akt activation. It remains unclear the hierarchy of these 
phosphorylations residues in Akt activation. However, and considering the above, we cannot 
rule out the possibility that any residual activity of Akt may be present in the PDK1 mice.
One of the reasons that may explain the lack of studies assessing specifically the role of Akt 
in hepatic regeneration is the existence of different Akt isoforms. Although these Akt 
isoforms share high sequence homology and some functional redundancy, emerging 
evidence suggests distinct biological functions for each isoform. Therefore, it is necessary to 
perform analytic and systematic approaches to unveil the functional differences and overlaps 
of the Akt family members during liver regeneration. Specific gene-disruption has been a 
valuable tool to discern some of the pathways involved in tissue regeneration. In our study, 
we used this strategy and we investigated the role of Akt in liver regeneration by performing 
PH in mice with Akt1, Akt2, dual Akt1/Akt2 or triple Akt1/Akt2/FoxO1 hepatic deficiency. 
Our results showed that Akt1 and Akt2 act redundantly during liver regeneration, as neither 
Akt1 nor Akt2 showed any regenerative impairment alter PH. The role of Akt during 
hepatocellular proliferation only becomes apparent after dual hepatic suppression of Akt1 
and Akt2. This results contrast with the publications that suggest distinct roles for each Akt 
isoform. In this context, we recently published that despite the existence of isoform-substrate 
specificity for Akt in endothelial cells, overexpression of Akt2 can bypass the loss of Akt1 
and phosphorylates Akt1 targets (13). These observations suggest that in the context of 
single hepatic deficiency of Akt1 or Akt2, overexpression of the remaining Akt isoform 
would be sufficient to enable the regeneration of the liver.
A novel contribution of our study is that Akt activity is required for both hepatocellular 
hypertrophy and proliferation. In the context of hypertrophy, the cell area of the DLKO 
hepatocytes was significantly diminished in basal conditions and may account for the 
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significant reduction of the “liver weight / total body weight” ratio observed in DLKO livers 
before PH. This observation is in agreement with previous reports showing impaired 
hepatocellular hypertrophy in partially hepatectomized PDK1 knockout mice and general 
growth defect in Akt1-null mice (19, 47, 48). However, we also showed that hepatic dual 
Akt1/Akt2 deficiency dramatically affects hepatocellular proliferation. More importantly, 
the triple hepatic deficiency of FoxO1, Akt1 and Akt2 recovered the hepatocellular mitotic 
response induced by PH in Akt deficient mice, but failed to significantly increase cellular 
hypertrophy. The results obtained using partially hepatectomized TLKO mice and primary 
hepatocytes treated with the AS1842856 inhibitor, indicate that Akt mediates cell 
proliferation through FoxO1 inhibition. By contrast, FoxO1 activity is not directly involved 
in hepatocellular hypertrophy; suggesting that other downstream Akt targets, such as 
PRAS40 and TSC2, may be responsible for cell growth after PH. Consistent with this 
notion, “liver weight/total body weight” ratio of TLKO mice remained lower than wild-type 
mice despite the recovery in cell proliferation and the normalization of the survival rate of 
partially hepatectomyzed TLKO.
The FoxO subclass of forkhead-box transcripition factors is constituted by FoxO1, FoxO3, 
FoxO4 and FoxO6. The FoxO members are evolutionary conserved and despite their 
diversification they share in common that all of them are downstream effectors of Akt. Akt 
inhibits FoxO1 by direct phosphorylation on the residues T24, S253 and S316 (mouse 
sequence). This posttranslational modification excludes FoxO1 from the nucleus and makes 
the protein more susceptible to ubiquitination and proteasome degradation (49–51). FoxO1 
regulate a significant number of cellular processes including the regulation of the cell cycle 
machinery (49, 52). In the present study, hepatic Akt deficiency was associated with barely 
detectable levels of CCND1 expression and impaired hepatocellular proliferation after PH. 
Interestingly; FoxO1 deficiency was able to restore CCND1 expression in the same Akt 
deficient context. This finding is relevant considering that D-type Cyclins are expressed 
early in the cells in response to mitogenic signals and that they play a necessary role 
allowing G1/S phase transition through the inactivation of the S-phase repressor pRb (53). 
We also showed that the pharmacological inhibition of FoxO1 in primary hepatocytes was 
associated with overexpression of CCND1. Our results are in agreement with other studies 
where the authors demonstrated that overexpression or conditional activation of FoxO 
proteins downregulated the expression of D-type Cyclins (54). Additionally, we showed that 
primary hepatocytes treated in vitro with AS1842856 up-regulated PCNA and Ki-67 
expression. Therefore, we cannot rule out the possibility that other components of the cell 
cycle machinery regulated by FoxO --such as p21, p27, CCND1, p130, cyclin G2 and polo-
like kinases-- may also contribute to the reestablishment of the cell proliferation observed in 
TLKO mice.
Partially hepatectomized DLKO mice show a profound metabolic imbalance characterized 
by hyperglycemia and the lack of both glycogen and lipid droplets in hepatocytes. Strikingly, 
all these deficiencies are restored in TLKO mice. In the context of the glucose metabolism, 
our results reproduce what have already been reported by others (25). In brief, mice with 
hepatic deletion of Akt1 and Akt2 are glucose intolerant and insulin resistant and these 
defects are normalized upon liver–specific deletion of FoxO1. The predominant mechanism 
behind this phenotype is sustained on the reported ability of FoxO1 to activate the 
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transcription of rate-limiting enzymes of gluconeogenesis, such as glucose-6-phosphatase 
and phosphoenolpyruvate carboxykinase (55, 56). Therefore, the activation of FoxO1 in an 
Akt deficient context would increase the rate of gluconeogenesis and glycogenolysis, which 
is concordant to what we found in the DLKO mice after PH. More intriguingly is the effect 
of hepatic Akt deficiency in lipid metabolism before and after PH. In this context, DLKO 
mice failed to accumulate lipid droplets following PH. Lipid droplets are mainly composed 
of triacylglycerol and cholesteryl esters (28). Consistent with this notion, the hepatic 
lipidome of DLKO mice showed a lack of CE accumulation throughout all the experimental 
points before and after PH and a significant decrease of triglyceride levels at 0 and 2 days 
post-hepatectomy. Notably, liver–specific deletion of FoxO1 in Akt deficient mice corrected 
these lipid abnormalities. Several studies may provide insight into the observed relationship 
between FoxO1 activation and lipid-cholesterol metabolism. For instance, AFPCre-
FoxO1loxP/loxP mice that were fasted overnight and then refed displayed increased hepatic 
TG levels compared to controls (57). A second study shows that FoxO1 inhibits the 
expression of the sterol element binding protein 1 (SREBP1), a transcriptional factor that 
regulates hepatic lipogenesis, thereby reducing hepatic lipid synthesis. Moreover, FoxO1 
might influence hepatic lipid droplet accumulation by increasing the expression of 
microsomal triglyceride transfer protein (MTP), which is a protein required for assembly of 
very-low density lipoprotein (VLDL) (58). In this regard, Kamagate et al demonstrated that 
mice in a fed state downregulate MTP expression through Akt-mediated FoxO1 inactivation 
(59). This signaling cascade resulted in reduced VLDL formation and, therefore, 
accumulation of lipid droplets into hepatocytes. These observations could explain the 
phenotype observed in DLKO and TLKO mice. However, further studies would be needed to 
better understand the pathophysiology of lipid abnormalities in partially hepatectomized 
DLKO mice. Nevertheless, our results unravel a major role of the Akt/FoxO1 pathway as a 
major regulator during liver regeneration.
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Figure 1. FoxO1 genetic deletion rescue the impaired liver regeneration and increased mortality 
observed in DLKO mice showed after PH
(A) Representative Western blot analysis of Akt (total Akt) in liver samples isolated from 
WT, Akt1−/−, Akt2−/− and DLKO mice. (B) Scatter plot of the hepatic regenerative index 
(Liver weight/Total body weight) obtained in WT, Akt1−/−, Akt2−/− and DLKO mice in 
basal conditions before PH. The central horizontal line in each group represents the mean ± 
S.E.M. (C) Liver to body weight ratio of WT, Akt1−/−, Akt2−/− and DLKO mice at the 
indicated time points before and after PH. Due to the mortality associated with the DLKO 
condition, the n varies from 2 to 10 among the different experimental groups. *P<0.01 vs 
WT, Akt1−/− and Akt2−/−; #P<0.01 vs the same experimental group on day 0, 4 and 
6; &P<0.05 vs the same experimental group on day 0 and 6; §P<0.01 vs the same 
experimental group on day 0 and 2. (D) Survival curves from WT, Akt1−/−, Akt2−/− and 
DLKO mice after PH were generated using the product limit method of Kaplan and Meier. 
The survival curves representing the WT, Akt1−/−, Akt2−/− and DLKO (n=10–12) mice were 
compared using the log-rang test. Black diamonds denote animals that died at follow-up. (E) 
Liver to body weight ratio of WT, DLKO and TLKO mice two days after PH. 
*P<0.05; #P<0.01..(F) Survival curves from WT and TLKO mice after PH were generated 
using the product limit method of Kaplan and Meier. The survival curves representing the 
WT (n=10) and the TLKO (n=10) mice were compared using the log-rang test. Black 
squares denote animals that died at follow-up. (G) Blood glucose concentration was 
measured in WT, DLKO and TLKO before and after PH. Data are expressed as mean ± 
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S.E.M., (n=10). *P<0.05 compared with WT mice at the same time points, #P<0.05 
compared with WT and TLKO mice at the same time points.
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Figure 2. Morphometric analysis of hepatocyte cell area in response to partial hepatectomy
Representative H&E-stained sections of livers isolated from WT, DLKO and TLKO mice 
before (T=0) and after PH (2, 4 and 6 days). Morphometric analysis of cell area was 
analyzed as described in Material and Methods. Original magnification ×200. The bottom 
graph shows the computed-assisted quantification of hepatocyte cell area (mean) before and 
after PH. Mean ± S.E.M is shown. *P<0.05 vs. 0 days of the same experimental 
group, #P<0.001 vs. 0, 4 and 6 days of the same experimental group, &P<0.05 vs. 0 and 6 
days of the same experimental group and φP<0.001 vs. 0 and 2 days of the same 
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experimental group. The n varies from 2 to 10 among the different experimental groups due 
to the mortality associated with the DLKO condition.
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Figure 3. Loss of FoxO1 normalized the expression of CCND1 and PCNA in Akt-deficient 
regenerative livers
Western blot analysis of indicated proteins in livers lysated from WT, DLKO and TLKO 
before (T=0 days) and after PH (T=2 and 4 days). HSP90 and tubulin were used as loading 
controls. The right panels show the densitometry analysis of hepatic CCND1 and PCNA 
expression in WT, DLKO and TLKO before and after PH. Results are represented as mean ± 
S.E.M. *P<0.05 vs. WT at the same day.
Pauta et al. Page 21













Figure 4. Genetic ablation of FoxO1 restored cell proliferation in Akt-deficient regenerative 
livers
(A–D) Representative immunofluorescence pictures for the Ki-67 positive cells in WT, 
DLKO and TLKO livers at 0 (A), 2 (B), 4 (C) and 6 (D) days following PH. Merged images 
on right panels show co-localization of Ki-67 (red) and nuclear DNA (DAPI, blue). Original 
magnification 100×, (n=2 to 10). The bottom graph (E) shows the computed-assisted 
quantification of positive Ki-67 cells / total nuclei at different times following PH. Mean ± 
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S.E.M is shown. *P<0.001 vs. WT and TLKO at the same day, #P<0.01 vs. WT at the same 
day, &P<0.05 vs. WT and DLKO at the same day.
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Figure 5. Genetic ablation of FoxO1 in Akt deficient livers restored lipid droplet formation and 
nearly normalized the hepatic lipidome after partial hepatectomy
(A) Representative histological panels of Oil red O-staining (red) in liver sections from WT, 
DLKO and TLKO mice before and after 2, 4 and 6 days of PH. Original magnification 200×, 
n= 3 to 5 animals. (B) Hepatic content of cholesterol ester (CE), phosphatidylethanolamine 
(PE), phosphatidylcholine (PC), sphingomyelin (SM), triglycerides and free fatty acids 
(FFA) in liver tissue isolated from WT, DLKO and TLKO mice. Zero-h data was obtained 
prior PH. Mean ± S.E.M is shown. *P<0.05 vs. WT and TLKO at the same time 
points, #P<0.01 vs. WT at the same time points, &P<0.05 vs. WT and DLKO at the same 
time points. The n varies from 2 to 10 among the different experimental groups due to the 
mortality associated with the DLKO condition.
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